18 articles, transcripts, and reports
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) Wednesday said its third-quarter earnings increased, aided by higher revenues. The results also exceeded the market’s prediction. Adjusted…
Gilead Sciences Inc (NASDAQ: GILD) Q2 2020 earnings call dated July 30, 2020 Corporate Participants: Douglas Maffei — Senior Director, Investor Relations Daniel O’Day — Chairman and Chief Executive…
Gilead Sciences (NASDAQ: GILD) reported second-quarter financial results after the closing bell on Thursday. The biotechnology firm missed both the revenue and earnings estimates for…
Gilead Sciences Inc. (GILD) Q1 2020 earnings call dated April 30, 2020 Corporate Participants: Douglas Maffei — Investor Relations Daniel O’Day — Chairman and Chief Executive Officer Andrew Dickinson — Chief…
Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) Thursday said its first-quarter earnings increased, aided by higher revenues. The results also exceeded the market’s prediction. The…
Gilead Sciences Inc (NASDAQ: GILD) Q4 2019 Earnings Conference Call February 04, 2020 Corporate Participants: Douglas Maffei — Investor Relations Daniel O’Day — Chairman and Chief Executive Officer Andrew Dickinson — Chief…
Biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) reported a decline in fourth-quarter earnings, despite a modest increase in revenues. Earnings fell short of expectations, while…
— Gilead Sciences (NYSE: GILD) reported third-quarter 2019 earnings of $1.75 per share, vs. $1.74 per share expected. — Total revenue remained flat at $5.60…
